ACRO Biomedical Co., Ltd., the first company in the world to utilize 
"supercritical CO2 extraction technology" on cleansing animal tissues and 
organs, is gradually showing impressive results on the global patent map. In 
2019, ACRO acquired two patents from Japan. One for the decellularized 
cartilage graft, and another for the decellularized cornea. The great news 
continues with ACRO acquiring patents from the USA and Korea successively for 
the decellularized cornea in March 2020.

ACRO has acquired patents from Taiwan, the USA, Japan, and Korea for the 
preparation of acellular corneas by utilizing supercritical CO2 extraction 
technology. Patents from India, EU, Hong Kong, and mainland China are also on 
their way. The wish to benefit patients around the world with damaged cornea is 
very promising.

The CEO of ACRO Biomedical, DJ Hsieh, said that the traditional way to utilize 
supercritical CO2 extraction technology is to extract herbal medicine and 
essential oil. After many years of research and development, ACRO has 
successfully utilized the technology on cleansing animal tissues and organs 
including skin, bone, cartilage, cornea, blood vessel, nerve, heart, kidney, 
liver, pancreas, and brain. Many of the products have received approval from 
USFDA, Singapore, Vietnam, Philippines, and Taiwan FDA. Furthermore, ACRO has 
licensed out Collagen Ophthalmic Matrix to Oculus BioMed from Australia, and 
also signed an exclusive strategic partnership agreement with Marubeni 
Corporation from Japan, laying the foundation for the global market.

The advantages of ACRO's technology application are its high efficiency, low 
cost, time-saving, and when compared with other products of the same type that 
are decellularized with acid-base solutions or organic solvents, it greatly 
reduces the chance of allergy and immune rejection. It is a great help for the 
future development of the global regenerative medicine.

SOURCE ACRO Biomedical Co., Ltd.